Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.

Wang X, Qin J, Liu Y, Wang X

Journal of diabetes investigation28 Mar 2026Cited by 1 (Europe PMC)

PMID41902544 (opens in a new tab)PMCIDPMC13238613 (opens in a new tab)DOI10.1111/jdi.70293 (opens in a new tab)PepBankPUB-41902544
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with type 2 diabetes, insulin degludec/liraglutide had more treatment-emergent adverse events than insulin degludec/aspart (OR 1.69, 95% CI 1.08-2.65).

    In plain wordsIn people with type 2 diabetes, insulin degludec/liraglutide had more treatment-emergent adverse events than insulin degludec/aspart.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment-emergent adverse events
    Study

    n: not reported in source

    Comparator
    IDegAsp
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Both IDegLira (OR = 1.69, 95% CI: 1.08-2.65) and iGlarLixi (OR = 1.67, 95% CI: 1.17-2.37) had a higher incidence of treatment-emergent adverse events (TEAEs) than IDegAsp; no other significant pairwise differences were observed.
    4 context sentences
    Summary · context
    To systematically evaluate and compare the efficacy and safety of three fixed-ratio combination products-insulin degludec/liraglutide (IDegLira), insulin glargine/lixisenatide (iGlarLixi), and insulin degludec/insulin aspart (IDegAsp)-in patients with type 2 diabetes.
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP up to July 2025 for randomized controlled trials (RCTs) comparing the three combinations of primary interest (IDegLira, iGlarLixi, IDegAsp) and their individual components (insulin degludec, insulin glargine, liraglu…
    Summary · context
    Network meta-analysis was conducted using Stata 14.0, with treatments ranked by the surface under the cumulative ranking curve (SUCRA).
    Summary · context
    Inconsistency in the hypoglycemia network, likely due to varied definitions, warrants cautious interpretation.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, insulin degludec/liraglutide had an 89.4% probability of being optimal for HbA1c reduction in the SUCRA ranking.

    In plain wordsIn people with type 2 diabetes, insulin degludec/liraglutide had an 89.4% SUCRA probability for best HbA1c reduction.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c reduction ranking
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Based on SUCRA values, which provide a probabilistic ranking (indicating the likelihood of being the best rather than direct statistical superiority), IDegLira had the highest probability of being optimal for reducing HbA1c (89.4%), fasting plasma glucose (81.8%), and incidence of hypoglycemic event…
    4 context sentences
    Summary · context
    To systematically evaluate and compare the efficacy and safety of three fixed-ratio combination products-insulin degludec/liraglutide (IDegLira), insulin glargine/lixisenatide (iGlarLixi), and insulin degludec/insulin aspart (IDegAsp)-in patients with type 2 diabetes.
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP up to July 2025 for randomized controlled trials (RCTs) comparing the three combinations of primary interest (IDegLira, iGlarLixi, IDegAsp) and their individual components (insulin degludec, insulin glargine, liraglu…
    Summary · context
    Network meta-analysis was conducted using Stata 14.0, with treatments ranked by the surface under the cumulative ranking curve (SUCRA).
    Summary · context
    Inconsistency in the hypoglycemia network, likely due to varied definitions, warrants cautious interpretation.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, insulin degludec/liraglutide had an 81.8% probability of being optimal for fasting plasma glucose reduction in the SUCRA ranking.

    In plain wordsIn people with type 2 diabetes, insulin degludec/liraglutide had an 81.8% SUCRA probability for best fasting-glucose reduction.

    Peptide
    Liraglutide
    Outcome
    Not applicableFasting plasma glucose reduction ranking
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Based on SUCRA values, which provide a probabilistic ranking (indicating the likelihood of being the best rather than direct statistical superiority), IDegLira had the highest probability of being optimal for reducing HbA1c (89.4%), fasting plasma glucose (81.8%), and incidence of hypoglycemic event…
    4 context sentences
    Summary · context
    To systematically evaluate and compare the efficacy and safety of three fixed-ratio combination products-insulin degludec/liraglutide (IDegLira), insulin glargine/lixisenatide (iGlarLixi), and insulin degludec/insulin aspart (IDegAsp)-in patients with type 2 diabetes.
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP up to July 2025 for randomized controlled trials (RCTs) comparing the three combinations of primary interest (IDegLira, iGlarLixi, IDegAsp) and their individual components (insulin degludec, insulin glargine, liraglu…
    Summary · context
    Network meta-analysis was conducted using Stata 14.0, with treatments ranked by the surface under the cumulative ranking curve (SUCRA).
    Summary · context
    Inconsistency in the hypoglycemia network, likely due to varied definitions, warrants cautious interpretation.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with type 2 diabetes, insulin degludec/liraglutide had a 57.6% probability of being optimal for lower hypoglycemic-event incidence in the SUCRA ranking.

    In plain wordsIn people with type 2 diabetes, insulin degludec/liraglutide had a 57.6% SUCRA probability for lower hypoglycemic-event incidence.

    Peptide
    Liraglutide
    Outcome
    Not applicableHypoglycemic-event incidence ranking
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Based on SUCRA values, which provide a probabilistic ranking (indicating the likelihood of being the best rather than direct statistical superiority), IDegLira had the highest probability of being optimal for reducing HbA1c (89.4%), fasting plasma glucose (81.8%), and incidence of hypoglycemic event…
    4 context sentences
    Summary · context
    To systematically evaluate and compare the efficacy and safety of three fixed-ratio combination products-insulin degludec/liraglutide (IDegLira), insulin glargine/lixisenatide (iGlarLixi), and insulin degludec/insulin aspart (IDegAsp)-in patients with type 2 diabetes.
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP up to July 2025 for randomized controlled trials (RCTs) comparing the three combinations of primary interest (IDegLira, iGlarLixi, IDegAsp) and their individual components (insulin degludec, insulin glargine, liraglu…
    Summary · context
    Network meta-analysis was conducted using Stata 14.0, with treatments ranked by the surface under the cumulative ranking curve (SUCRA).
    Summary · context
    Inconsistency in the hypoglycemia network, likely due to varied definitions, warrants cautious interpretation.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.